|
GSTT2 polymorphisms and colorectal cancer risk |
|||||||
| Locus |
HWE |
MAF |
Genotype |
Healthy controls (N = 568) |
CRC patients (N = 436) |
p |
OR(95% CI) |
|
|
|||||||
| -537 |
0.999 |
0.42 |
GG |
203 (35.7%) |
127 (29.1%) |
0.025 |
1.373 (1.041–1.810) |
| GA or AA |
365 (64.3%) |
309 (70.9%) |
|||||
| -277 |
0.548 |
0.07 |
TT |
489 (86.1%) |
388 (89.0%) |
0.125 |
0.735 (0.495–1.090) |
| TC or CC |
79 (13.9%) |
48 (11.0%) |
|||||
| -158 |
0.314 |
0.03 |
GG |
522 (91.9%) |
416 (95.4%) |
0.032 |
0.539 (0.307–0.947) |
| GA or AA |
46 (8.1%) |
20 (4.6%) |
|||||
|
Adjusted for age and sex; HWE: Hardy-Weinberg equilibrium for controls; MAF: Minor allele frequency Dominant model: Homozygote of major allele vs. heterozygote and homozygote of minor allele | |||||||
Jang et al. BMC Cancer 2007 7:16 doi:10.1186/1471-2407-7-16 |
|||||||